Delivering unparalleled reach and expertise for diabetes and obesity trials worldwide

participants with diabetes and/or obesity enrolled

endocrinology and metabolism trials conducted

sites that can support diabetes and obesity trials

Velocity has conducted trials that have led to 20+ product approvals for diabetes, obesity, and dyslipidemia

The Velocity Diabetes and Obesity Council to Accelerate Research Excellence (CARE) develops best practices to guide recruitment, screening, trial conduct, and retention strategies for all Velocity sites. This council is led by renowned physicians with extensive research and medical practice experience, along with veteran operational leaders.

Given the high prevalence of obesity (40%+) and diabetes (11%+) among U.S. adults, these diseases represent a growing therapeutic need, particularly as children become increasingly affected by these diseases. While afflicted populations are large, the diversity of concurrent therapies and lifestyle considerations can quickly complicate clinical trial design, screening, and enrollment.

Reach and capabilities

10+ sites with extensive diabetes and obesity capabilities
On-site dietitians at key sites
Access to millions of patient lives
World-class diversity and community engagement initiatives
Expertise in diabetes-related device research, including continuous glucose monitoring

Diabetes and Obesity CARE Council Leader

Velocity's Diabetes and Obesity CARE Council is led by distinguished physician, Julio Rosenstock, MD. The council leverages his vast experience in diabetes and metabolism-related research, alongside Velocity sites and staff that have supported thousands of trials and offer access to millions of patient lives.

Let's Talk About Your Next Trial

Julio Rosenstock, MD

An internationally known opinion leader in type 2 diabetes, Dr. Rosenstock is Senior Scientific Advisor for Velocity, Director of Velocity’s site at Medical City Dallas, and Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, Dallas. Dr. Rosenstock has long focused on exploring novel agents and therapeutic strategies for glycemic control, and particularly early combination therapies for type 2 diabetes.

Over the last 30 years, he has participated in hundreds of clinical trials and has had an active role in the development of new oral agents, incretin-related therapies, and insulin preparations, often acting as a lead clinical investigator and scientific advisor on the design and reporting of clinical trials on novel diabetes drugs. Dr. Rosenstock has been the author or co-author of 375 peer-reviewed manuscripts (h-index 123) and hundreds of scientific abstracts. He is considered a key opinion leader in type 2 diabetes.

A transformative model to confront the inefficiencies that plague clinical trials

1: Drug Development Technology. (2012). Clinical trial delays: America’s patient recruitment dilemma. | 2: Tufts Center for the Study of Drug Development. (2013). Impact report: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Vol. 15, No. 1. | 3: Kaitin, K. I. (2006). Fastest drug developers consistently best peers on key performance metrics. Tufts Center for the Study of Drug Development Impact Report, 8(5). | 4: Hess, J. (n.d.). Web-based patient recruitment: best opportunity to accelerate clinical trials.

of U.S. trials fail to meet enrollment timelines

of sites miss enrollment targets

daily operational losses for Sponsors for delayed trials

$k+

potential daily opportunity cost losses for delayed trials

In the News

Velocity Investigators Active at the American Diabetes Association (ADA) 83rd Scientific Sessions

Julio Rosenstock, MD, and Juan Frias, MD, were featured prominently throughout the American Diabetes Association (ADA) 83rd Scientific Sessions. The prolific researchers also had findings simultaneously published in the New England Journal of Medicine and The Lancet. Dr. Rosenstock is the lead investigator for Novo Nordisk’s ONWARDS 1 program exploring the first investigational once-weekly insulin. “In ONWARDS 1, insulin icodec allowed people to spend significantly more Time in Range, with comparable Time below Range vs. once-daily basal insulin glargine U100,” … Read more

PI Focus: Velocity PI Leads Breakthrough Efforts to Combat Obesity, Diabetes

The Velocity Clinical Research team in Los Angeles, CA, is tackling two of the biggest health threats to Americans today: obesity and diabetes. Better still, they’re making tremendous progress against these conditions that exact a terrible toll on quality of life and longevity. Consider these sobering statistics from the Centers for Disease Control and Protection (CDC): The U.S. obesity prevalence was 42% in 2017 – March 2020. (NHANES, 2021) Compared to 20 years ago, U.S. obesity prevalence increased from 30.5% … Read more

Let's talk about your next trial

I am a...(Required)

Submissions on this website are not monitored 24/7. Please do not submit personal health or medical information in this form. If you are currently enrolled in a trial and have questions, please call your research site. By entering your email address and/or phone number and submitting this form, you consent to Velocity's privacy policy and receiving communications (e.g., call and/or email) from Velocity about current and future studies.

Name(Required)

First Last

Company(Required)

Phone (Optional)

Email(Required)

What is your therapeutic specialty?(Required)

(E.g., neurology, general medicine, dermatology)

What is your average number of active studies per year?(Required)

Have you previously conducted research?(Required)

Is your clinic part of a medical practice?(Required)

Your Site or Practice Address

City State ZIP Code

Select the Velocity location nearest you.(Required)

This will help direct your message to the right Velocity location.

Hidden

In which city and state/region are you located?(Required)

This will help direct your message to the right Velocity location.

Message

Describe your clinical trial, research program, or development goals.

Message

Captcha

Comments

This field is for validation purposes and should be left unchanged.